Novo Nordisk Faces More Pain: Bernstein Initiates Underperform Coverage
Bernstein initiates Underperform on Novo Nordisk, citing endless earnings downgrades, weak catalysts, U.S. price deflation, and 2032 patent cliff risks.
/ 97 items
#NVO↓
Structure Therapeutics' Oral Obesity Pill Aleniglipron Hits Record 16.3% Weight Loss in Phase 2 Trial – Matches Injectables with No Plateau
Structure Therapeutics' oral pill aleniglipron achieved 15–16% body weight loss (up to 39 lbs) after 44 weeks in Phase 2, rivaling injectables with better tolerability and no plateau. Phase 3 is planned for 2026—a potential game changer for obesity treatment.
FDA Issues Warning Letter to Novo Nordisk Over Delayed Safety Reports for Ozempic and Victoza
Novo Nordisk receives FDA warning letter after 2025 Plainsboro inspection revealed failures in timely reporting serious side effects for drugs like Ozempic and Victoza. Company says no impact on production.
Novo & Hims Partner on Ozempic & Wegovy – Lawsuit Dropped
Novo Nordisk and Hims & Hers end their legal battle and team up to offer FDA-approved Ozempic and Wegovy (injections and pills) on the Hims platform. Hims shifts its focus to branded GLP-1s with limited compounded options. Shares surge.
From Lawsuit to Love: Novo Nordisk Teams Up with Hims & Hers Again
Novo Nordisk is set to sell its popular weight-loss drugs like Wegovy on Hims & Hers platform soon, surprising many after a recent lawsuit over copycat versions. This could boost access and help both companies in the competitive obesity market.
FDA Cracks Down Hard — 30 Telehealth Companies Warned Over Compounded Ozempic & Zepbound Copies
The FDA sent warning letters to 30 telehealth companies for false claims about compounded GLP-1 drugs like semaglutide and tirzepatide.